On the 7th, GC Pharma announced that it had received approval for a Phase I trial of its severe Hunter syndrome treatment ‘Hunterase ICV’ in Korea from the Ministry of Food and Drug Safety.

Hunterase ICV comes in a new formulation that is inserted as a device in the head, through which a drug is directly administered into a patient’s cerebral ventricle. It overcomes the limitations of existing IV-type formulations that were unable to penetrate the blood brain barrier (BBB) and reach the cerebral parenchyma.

The clinical trial will be conducted in 3 institutions in Korea - the Samsun Medical Center, Seoul National University Hospital, and Pusan National University Yangsan Hospital &#